* LifeMD Inc LFMD.OQ LFMD.O is expected to show a rise
in
quarterly revenue when it reports results on August 9.
* The New York City-based company is expected to report a
15.5% increase in revenue to $35.165 million from $30.46 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. The company's guidance on May 12 2023,
for the period ended June 30, was for revenue between $35.00
million and $36.00 million.
* Refinitiv's mean analyst estimate for LifeMD Inc is for a
loss
of 10 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for LifeMD Inc
is
$7, above its last closing price of $3.92.
The company's guidance on May 12 2023 for the period ended June
30 was for Earnings before Interest, Taxes, Depreciation and
Amortization of between USD35 million and USD3.5 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.16 -0.16 -0.15 Beat 6.3
Dec. 31 2023 -0.18 -0.18 -0.40 Missed -122.2
Sep. 30 2022 -0.30 -0.28 -0.26 Beat 8.8
Jun. 30 2022 -0.35 -0.35 -0.45 Missed -28.6
Mar. -0.41 -0.36 -0.46 Missed -26
31 2022
Dec. 31 2021 -0.42 -0.42 -0.62 Missed -45.9
Sep. 30 2021 -0.62 -0.62 -0.54 Beat 12.9
Jun. 30 2021 -0.53 -0.53 -0.64 Missed -20.8
This summary was machine generated August 7 at 23:57 GMT. All
figures in US dollars unless otherwise stated